Latest News Releases

PTA-Adhoc: Biofrontera AG: Forecast Increase

Public disclosure of inside information according to article 17 MAR

Leverkusen (pta003/14.02.2026/13:15) - Biofrontera AG is raising its forecast for the fiscal year 2025. Based on preliminary figures, EBITDA is expected to be between EUR 3.5 million and EUR 5 million (previous expectation: EUR 1.5 million to EUR 3.5 million). The previous revenue forecast of EUR 17 million to EUR 20 million remains unchanged.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com

ISIN(s): DE000A4BGGM7 (share)
stock exchanges: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Tradegate BSX

[ source: https://www.pressetext.com/news/20260214003 ]

Biofrontera AG – an attractive investment

We are experts in photodynamic therapy. With our innovative products and treatment methods, we make our contribution to skin health and at the same time create value for our investors.

Biofrontera is listed on the Frankfurt Stock Exchange (B8FK).